Deep Track Capital’s Generate Biomedicines GENB Stock Holding History

Deep Track Capital’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.5M	Buy	+1,333,815	New	+$18.2M	0.33%	53

Other funds holding GENB

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Deep Track Capital's GENB Position: Q2 2026 in Review

Deep Track Capital opened a new position in Generate Biomedicines (GENB) in Q2 2026: 1,333,815 shares worth $22.5M. The stake represents 0.33% of the portfolio and ranks #53 among its holdings.

81 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

Deep Track Capital held 1,333,815 shares of Generate Biomedicines worth $22.5M as of Q2 2026.
Generate Biomedicines was a new Deep Track Capital position in Q2 2026.
Generate Biomedicines made up 0.33% of Deep Track Capital's portfolio in Q2 2026, its #53 holding.
81 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.